Matthias Guckenberger

❓ Role of SBRT-only in hormone-sensitive oligometastatic prostate cancer ❓ Value of 6-months ADT added to SBRT ❓ Appropriate endpoints Virtual Grand Rounds in Radiation Oncology usz.ch/en/events/virt… Proudly presenting: @BarbaraJereczek Wed April 2nd 17:00 – 17:30 CET 👇

❓ What is the optimal duration of ADT if combined with EBRT for definitive treatment of prostate cancer Virtual Grand Rounds in Radiation Oncology 🎙 Speaker: Dr. @NicholasZaorsky 📅 February 4th, 5 - 5.30 pm CET 💻 Join us virtually here: 👇 usz.ch/en/events/virt…

@GiuliaMarvaso84 @drdavidpalma Not missing at all, different study question 😎 The overview shows SoC vs SoC + MDT

@drdavidpalma @Mat_Guc Also Radiosa is missing 😪

Here are all the oligomets RCTs. HRs < 1 in green. @Mat_Guc

@drdavidpalma @adelapoite @piet_ost Thanks for participating and you 💪💪💪 support of the trial

Very excited to open EORTC-1945 today, OligoRARE! We hope to enroll a few patients before it finishes accrual. Thanks @Mat_Guc and @piet_ost for allowing some 🇨🇦!

Virtual Grand Rounds in Radiation Oncology 🥊 Battle of the Treatment Fields: Advancing Radiation Therapy for Leptomeningeal Metastasis 📅 Today Dr. Jonathan Yang 5pm - 5:30pm CEST Please join virtually here 👇 usz.ch/en/event/virtu…

ASTRO is deeply disturbed by the inaccurate, inappropriate, and irresponsible NBC News piece on IORT. We feel this story harms care for breast cancer patients & have strongly rebutted it through our Breast Cancer Resource Panel & a letter from ASTRO CEO, Vivek S Kavadi, MD to NBC News. Read each here: Breast Resource Panel Statement ow.ly/aicz50X9ty1 Letter to NBC News from Dr. Vivek S. Kavadi ow.ly/Hvy550X9txZ

Important prediction modeling for patients with oligometastatic cancer based on distant metastases velocity (DMV). Great collaboration and proud to contribute our @Sunnybrook data. No doubt that #SBRT is critical to advancing outcomes for these patients. pubmed.ncbi.nlm.nih.gov/40876085/

Join us for #ESTRO26 in Stockholm!!!

Great collaboration between MOMENTUM and Oligocare registries, presenting the preliminary outcomes (of 15 institutions) regarding liver SBRT using MRI or CT guided approach during #ESTRO2025 !

🎥 Exclusive interview this morning at #ESTRO25: We spoke with ESTRO President Prof Matthias Guckenberger about the congress highlights, this year’s theme of partnership, and the future of radiation oncology. Don’t miss his insights ⬇️ #Radiotherapy #CancerResearch @Mat_Guc

Greetings from #ESTRO25 and a wam welcome to #APCCC26 in Lugano 🇨🇭 @Silke_Gillessen @BarbaraJereczek @piet_ost @ZilliThomas @GiulioFrancoli1 @Mat_Guc @VedangMurthy @OncoAlert 🚨

SBRT + 💊 in oligomets: 🧍‍♂️2294 pts | 🫁, breast, prostate, colorectal ⚠️Grade 3+ AEs: 1.5% ✅ SBRT Safe with systemic tx! #SBRT #OligoCare #ESTRO25 @EORTC @ESTRO_RT @CiroFranzese1

Outstanding #ESTRO25 plenary talk from Uffer Pascal, an entrepreneur with stage 4 #lungcancer “What if radiation oncology was a start up” Highlights the 5’s: Collaborate Communicate Learn from every Customer Cost Efficiency Culture

📢 🚨#lungcancer peeps. Please consider Prof Andrea Bezjak from @UofT for your next IASLC president! A very deserving candidate and a great representative for #radonc!!! @ldawsonmd #lcsm

🎉We’re excited to announce that the first patient has been randomised in the SPRINT study! The patient was enrolled at Inselspital in Bern, under the supervision of PI Professor Hossein Hemmatazad. 👉 project.eortc.org/e2-radiate/202… #E2RADIatE #OligoCare @piet_ost @Mat_Guc

🏅 Interview with Dirk Verellen, recipient of the Emmanuel van der Schueren Award at #ESTRO25: Don’t miss his award lecture in Vienna! 📆 Saturday 3 May | 14:15 - 14:40 CEST | Plenary Hall 👉 Full interview here: bit.ly/4ifJd75 #Radonc #OncologyInnovation #ESTROAwards

SANO trial: non-surgical approach & organ preservation in pts esophageal cancer and complete clinical response after neoadjuvant RCT Virtual Grand Rounds in Radiation Oncology usz.ch/en/events/virt… Wednesday May 7th 17:00 – 17:30 - Safe the date ! Berend van der Wilk

This Wednesday 👇

#ELCC25 in Paris has started with @ESTRO_RT being a partner of the meeting Such multidisciplinary meetings are THE place to learn from our neighboring disciplines & teach them about the value of Radiation Oncology Tomorrow: borderline resectable stage III NSCLC, hot topic

Health Business International conference in Paris Change of perspective on health care, financial models and opportunities for collaboration between academic public, and private sectors